Weinfeld M S, Drazner M H, Stevenson W G, Stevenson L W
Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Heart Lung Transplant. 2000 Jul;19(7):638-43. doi: 10.1016/s1053-2498(00)00123-6.
Little information exists about the early outcomes of initiating amiodarone for atrial fibrillation in patients with advanced heart failure. This study assessed the initial rate of success and complications of amiodarone therapy initiated for patients with atrial fibrillation during hospitalization for heart failure.
We reviewed medical records for 37 consecutive patients with left ventricular ejection fractions </=40% who underwent initiation of amiodarone for atrial fibrillation during hospitalization on a heart failure service.
Atrial fibrillation was present in 35 (95%) and atrial flutter in 2 (5%), with mean duration of 30 months. New York Heart Association class was 3.1 (+/-1.1). Left ventricular ejection fraction was 24% +/- 7%. All patients had received oral amiodarone with an initial dose of 1.2 +/- 0.2 g/day. Bradyarrhythmia led to discontinuation of digoxin in 12 (32%) patients and to permanent pacemaker placement in 7 (19%) patients. Conversion to sinus rhythm occurred spontaneously in 2 patients and after electrical cardioversion in 26 patients, for an initial success of 76%. After a median follow-up of 9.5 months, 21 of 37 (57%) patients remained in sinus or atrial-paced rhythm. Amiodarone complications occurred after discharge in 5 (14%) patients, 4 with hypothyroidism.
Amiodarone with electrical cardioversion has a high initial success rate for treatment of atrial fibrillation in patients with heart failure with advanced systolic dysfunction. The major early side effect was bradyarrhythmia, frequently requiring discontinuation of digoxin or permanent pacemaker placement.
关于晚期心力衰竭患者开始使用胺碘酮治疗心房颤动的早期结果,目前所知甚少。本研究评估了因心力衰竭住院期间开始使用胺碘酮治疗心房颤动患者的初始成功率和并发症情况。
我们回顾了37例连续住院的左心室射血分数≤40%且因心力衰竭接受胺碘酮治疗心房颤动的患者的病历。
35例(95%)为心房颤动,2例(5%)为心房扑动,平均持续时间为30个月。纽约心脏协会心功能分级为3.1(±1.1)级。左心室射血分数为24%±7%。所有患者均接受口服胺碘酮,初始剂量为1.2±0.2g/天。缓慢性心律失常致使12例(32%)患者停用洋地黄,7例(19%)患者植入永久性起搏器。2例患者自发转为窦性心律,26例患者经电复律后转为窦性心律,初始成功率为76%。中位随访9.5个月后,37例患者中有21例(57%)维持窦性或心房起搏心律。5例(14%)患者出院后出现胺碘酮相关并发症,4例为甲状腺功能减退。
对于晚期收缩功能障碍性心力衰竭患者,胺碘酮联合电复律治疗心房颤动的初始成功率较高。主要的早期副作用是缓慢性心律失常,常需停用洋地黄或植入永久性起搏器。